NEW YORK EYE AND EAR INFIRMARY — History
CCN 330100 | 3-year financial timeline | COVID resilience: 75/100
🛡️ Public data only — no PHI permitted on this instance.
$113M
Latest Revenue (FY2022)
+3.4%
Revenue CAGR (3yr)
-28.0%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $106M | $121M | $113M | -6.8% | +3.4% |
| Operating Expenses | $142M | $146M | $144M | -1.1% | +0.8% |
| Operating Margin | -34.4% | -20.6% | -28.0% | -35.9% | +0.0% |
| Net Income | $-36M | $-25M | $-32M | -26.7% | +0.0% |
| Licensed Beds | 13 | 17 | 15 | -11.8% | +7.4% |
| Total Patient Days | 765 | 981 | 812 | -17.2% | +3.0% |
| Medicare Day % | 2% | 3% | 1% | -56.5% | -19.2% |
| Medicaid Day % | 0% | nan% | 0% | +nan% | -2.9% |
COVID Impact & Recovery
Resilience Score: 75/100 — Resilient — strong COVID recovery
Revenue recovery from FY2020 to FY2022: +6.8% ($106M → $113M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▲ Growing
Beds▲ Growing
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
+3.4%
This Hospital
+7.6%
State Avg
Latest Margin
-28.0%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $116M | -24.7% |
| FY2024 (proj) | $120M | -21.5% |
| FY2025 (proj) | $124M | -18.3% |